Novo Nordisk, the maker of Ozempic, aims to enter the hair-loss market as part of its strategy to diversify and leverage its ...

European pharmaceutical companies urge governments to enhance spending and streamline drug trials to compete with the US and ...

Amgen's late-stage trial results for dazodalibep, an experimental drug for Sjogren's disease, indicate significant reduction in disease activity, leading to a 4% surge in shares. Discover the ...

Cohance Lifesciences' API manufacturing site in Andhra Pradesh has received a Form 483 with five observations from the FDA, ...

The sale comes amid rising competition from brands such as Ayvakit, marketed by French major Sanofi. However, direct generic competition is expected to arrive only after 2029 in Europe and 2030 in the ...

Approximately 96% completion, every certificate accounted for, with nothing overdue – this is what a quality head at an Indian formulation plant can pull up from her training dashboard in less than a ...

India's DCGI warns against the indiscriminate use of painkillers and antibiotics due to risks of chronic kidney disease, urging healthcare professionals to adhere to strict guidelines for medication.

Of the total 220 NSQ samples identified in August, includes several common medicines such as paracetamol, metformin combos (for diabetes), amoxicillin formulations (antibiotics), vitamin supplements ...

Novo Nordisk's CagriSema shows significant weight loss benefits in diabetes patients, surpassing Eli Lilly's tirzepatide in ...

Beacon Therapeutics has announced that their experimental gene therapy, laru-zova, significantly improves reading ability in ...

The biosimilar alternative, branded as Pebrilzo, is cleared for the treatment of HER2-positive breast cancer across multiple ...

The San Diego, California -based ‌company is aiming to raise up to $371.9 million in the IPO by offering 21.9 million shares priced between $15 and $17 each.